Arnott S., Nutt D.J. (1994) Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatr164: 838-839
2.
Bersani G., Grispini A., Marini S., Pasini A., Valducci M., Ciani N. (1990) 5HT-2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. Clin Neuropharmacol13: 500-506
3.
Claus A., Bollen J., De Cuyper J., Eneman M., Malfroid M., Peuskens J., Heylen S. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenia in patients: a multicentre double-blind comparative study. Acta Psychiatr Scand85: 295-305
4.
Farde L., Wiesel F., Halldin C., Sedvall G. (1988) Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatr45: 71-76
5.
Ghika J., Tennis M., Hoffman B.A., Schoenfeld D., Growden J. (1991) Idazoxan treatment in progressive supranuclear palsy. Neurology41: 986-991
6.
Glue P., Nutt D.J. (1988) Clonidine challenge testing of alpha-2-adrenoceptor function in man: effects of mental illness and psychotropic medication. J Psychopharmacol2: 119-137
7.
Glue P., White E., Wilson S., Ball D., Nutt D.J. (1991) The pharmacology of saccadic eye movements (2): effects of the α-2-adrenoceptor ligands idazoxan and clonidine. Psychopharmacology105: 368-373
8.
Greenhoff J., Svensson T.H. (1989) Clonidine modulates dopamine cell firing in the rat ventral tegmental area. J Pharmacol165: 11-18
9.
Herve D., Blanc G., Glowinski J., Tassin J.P. (1982) Reduction of dopamine utilization in the prefrontal cortex but not in the nucleus accumbens after selective destruction of noradrenergic fibres innervating the ventral tegmental area in the rat. Brain Res237: 510-516
10.
Idzikowski C., Cowen P.J., Nutt D.J., Mills F.J. (1987) The effects of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology93: 416-420
11.
Leysen J.E., Janssen P M F, Schotte A., Luyten W H M L, Megens A A H P (1993) Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology112: S40-S54
12.
Litman R.E., Hong W.W., Weissman E.M., Su T.P., Potter W.Z., Pickar D. (1993) Idazoxan, an α-2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study. J Clin Pharmacol13: 264-267
13.
Maj J., Mogilnicka E., Przewlocka B. (1975) Antagonistic effect of cyproheptadine on neuroleptic-induced catalepsy. Pharmacol Biochem Behav3: 25-27
14.
Meltzer H.Y., Nash J.F. (1991) Effects of antipsychotic drugs on serotonin receptors . Pharmacol Rev43: 587-604
15.
Murphy D.L., Mueller E.A., Hill J.L., Tolliver T.J., Jacobsen F.M. (1989) Comparative anxiogenic neuroendocrine and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology98: 275-282
16.
Nutt D.J. (1992) Neurochemistry and neuropharmacology. In Morgan H G, Butler S (eds), College seminars in psychiatry: basic neurosciences. Royal College of Psychiatrists, London, pp. 71-111
17.
Nutt D.J., Lalies M., Hudson A. (1993) The effects of alpha-2-adrenoceptor antagonists on extracellular dopamine concentrations in rat striatum. In Colpaert F, Briley M (eds), Noradrenergic mechanisms in Parkinson's disease. Academic Press, New York, pp. 159-172
18.
Osman O.T., Rudorfer M.V., Potter W.Z. (1989) Chronic alpha-2 antagonism increases norepinephrine, blocks GH release and is antidepressant. Biological Psychiatry Meeting, San Francisco, CA (Abstract)
19.
Pickar D., Owen R.R., Litman R.E., Komcki P.E., Gutierrez R., Rapaport M.H. (1992) Clinical and biological response to clozapine in patients with schizophrenia: crossover comparison with fluphenazine. Arch Gen Psychiatr49: 345-353
20.
Potkin S.G., Buchsbaum M., Jin Y., Wu J., Costa J., Gulasekaram B., Richmond G., Fallon J., Hong C., Telford J., Sitanggan K. (1994) Brain metabolic correlates of antipsychotic response . Neuropsychopharmacology10-3S: 696S
21.
Reyntgens A., Gelders Y.G., Hoppenbrouwers M-L J A, Vanden Bussche G. (1986) Thymostenic effects of ritanserin (R 55 667), a centrally acting serotonin-S2 receptor blocker. Drug Dev Res8: 205-211
22.
Sahakian B., Hodges J. (1994) Idazoxan improves cognitive function in frontal lobe dementia. J Neurol, Neurosurg Psychiatr57: 120-121
23.
Schittecatte M., Charles G., Machowski R., Garvia-Valentin J., Mendlewicz J., Wilmotte J. (1992) Reduced clonidine rapid eye movement sleep suppression in patients with primary major affective illness. Arch Gen Psychiatr49: 637-642
24.
Schmidt M.E., Matochik J.M., Risinger R.C., Leakan R.A., Potter W.Z. (1994) Gender differences in regional brain metabolism following acute idazoxan. Neuropsychopharmacology10-3S: 247S
25.
Seeman P. (1987) Dopamine receptors and the dopamine hypothesis of schizophrenia. Synapse1: 133-152
26.
Smith A.P., Wilson S.J., Glue P., Nutt D.J. (1992) The effects and after-effects of the alpha-2-adrenoceptor antagonist idazoxan on mood, memory and attention in normal volunteers. J Psychopharmacol6: 376-381
27.
Sokoloff P., Giros B., Martres M.P., Bouthenet M-L., Schwartz J-C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature347: 146-151
28.
Sokoloff P., Martres M-P., Giros B., Bouthenet M.-L, Schwartz J-C. (1992) The third dopamine receptor (D3) as a novel target for antipsychotics. Biochem Pharmacol43: 659-666
29.
Stein L., Wise C.D. (1971) Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxydopamine. Science171: 1032-1036
30.
Thomas D.N., Holman R.B. (1991) A microdialysis study of the regulation of endogenous noradrenaline release in the rat hippocampus. J Neurochem56: 1741-1746
31.
van Kammen D.P., Peters J., Yao J., van Kammen W.B., Neylan T., Shaw D., Linnoila M. (1990) Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatr47: 161-170
32.
Van Tol H H M, Bunzow J.R., Guan J-C., Sunahara R.K., Seeman P., Niznik J.B., Civelli O. (1990) Cloning of the gene for a human dopamine D 4 receptor with high affinity for the antipsychotic clozapine. Nature350: 610-614
